Loading...
XKRX
293780
Market cap174mUSD
Jul 11, Last price  
8,960.00KRW
1D
0.45%
1Q
19.79%
IPO
-77.82%
Name

AptaBio Therapeutics Inc

Chart & Performance

D1W1MN
No data to show
P/E
P/S
71.66
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
3.36b
+937.76%
323,868,8183,360,980,190
Net income
-29.38b
L+143.57%
-12,061,644,000-29,377,949,530
CFO
-12.16b
L-13.73%
-14,095,170,830-12,159,709,760
Dividend
Mar 15, 20220.285 KRW/sh

Profile

AptaBio Therapeutics Inc. discovers and develops selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The company offers Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX Reagent for transfecting DNA or RNA into eukaryotic cells. Its product candidates include PX-115 for treating diabetic nephropathy; APX-1004 to treat diabetic retinopathy; and APX-311 for use in treating non-alcoholic steatohepatitis (NASH). The company was founded in 2009 and is based in Yongin-Si, South Korea.
IPO date
Jun 12, 2019
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFY
2024‑122023‑12
Income
Revenues
3,360,980
937.76%
323,869
 
Cost of revenue
19,314,473
14,141,453
Unusual Expense (Income)
NOPBT
(15,953,493)
(13,817,584)
NOPBT Margin
Operating Taxes
1,575,110
(2,630,201)
Tax Rate
NOPAT
(17,528,603)
(11,187,383)
Net income
(29,377,950)
143.57%
(12,061,644)
 
Dividends
Dividend yield
Proceeds from repurchase of equity
(6,087)
BB yield
Debt
Debt current
7,398,995
131,075
Long-term debt
398,613
14,167,422
Deferred revenue
Other long-term liabilities
3,574,630
16,534,873
Net debt
(48,923,658)
(68,239,463)
Cash flow
Cash from operating activities
(12,159,710)
(14,095,171)
CAPEX
(240,162)
(167,391)
Cash from investing activities
12,853,535
(12,737,197)
Cash from financing activities
(167,306)
49,854,461
FCF
(13,830,801)
Balance
Cash
31,515,054
52,885,298
Long term investments
25,206,213
29,652,662
Excess cash
56,553,217
82,521,766
Stockholders' equity
(96,671,314)
(68,348,604)
Invested Capital
161,964,009
160,180,843
ROIC
ROCE
EV
Common stock shares outstanding
23,065
22,299
Price
Market cap
EV
EBITDA
(15,422,139)
(13,278,475)
EV/EBITDA
Interest
3,401,095
1,182,961
Interest/NOPBT